Niagen Bioscience (NAGE) Capital Expenditures (2011 - 2020)
Niagen Bioscience (NAGE) posted quarterly Capital Expenditures of $92000.0 for Q2 2020, up 33.33% year-over-year from $69000.0 in Q3 2019, and up 513.33% quarter-over-quarter from $15000.0 in Q1 2020.
Powered by 
Analysis
Niagen Bioscience (NAGE) Capital Expenditures (2011 - 2020) Analysis & Trends
Niagen Bioscience (NAGE) has reported Capital Expenditures for 8 consecutive years, with $92000.0 the latest figure, recorded in Q2 2020.
- In Q2 2020, Capital Expenditures rose 33.33% year-over-year to $92000.0; the TTM figure through Jun 2020 stood at $542000.0 (up 52.68% YoY), while the FY2019 annual figure was $743000.0, down 43.75% from the prior year.
- Capital Expenditures improved to $92000.0 in Q2 2020 per NAGE's latest filing, from $15000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.1 million in Q2 2018 and bottomed at $10000.0 in Q4 2018.
- Historically, Capital Expenditures has averaged $279722.4 across 5 years, with a median of $162000.0 in 2017.
- Annual changes were most pronounced in 2018 — Capital Expenditures sank 96.61% — and 2019, when it surged 2700.0%.
- Niagen Bioscience's Capital Expenditures stood at $563944.0 in 2016, then plunged by 47.69% to $295000.0 in 2017, then tumbled by 96.61% to $10000.0 in 2018, then soared by 2700.0% to $280000.0 in 2019, then tumbled by 67.14% to $92000.0 in 2020.
- Business Quant data shows NAGE's Capital Expenditures at $92000.0 in Q2 2020, $15000.0 in Q1 2020, and $280000.0 in Q4 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2020 | 92,000.00 |
| Mar 31, 2020 | 15,000.00 |
| Dec 31, 2019 | 280,000.00 |
| Sep 30, 2019 | 155,000.00 |
| Jun 30, 2019 | 69,000.00 |
| Mar 31, 2019 | 239,000.00 |
| Dec 31, 2018 | 10,000.00 |
| Sep 30, 2018 | 37,000.00 |
| Jun 30, 2018 | 1.11 Mn |
| Mar 31, 2018 | 161,000.00 |
| Dec 30, 2017 | 295,000.00 |
| Sep 30, 2017 | 577,000.00 |
| Jul 1, 2017 | 133,000.00 |
| Apr 1, 2017 | 162,000.00 |
| Dec 31, 2016 | 563,944.00 |
| Oct 1, 2016 | 709,777.00 |
| Jul 2, 2016 | 214,572.00 |
| Apr 2, 2016 | 16,629.00 |
| Jan 2, 2016 | 471,803.00 |
| Mar 30, 2013 | 7,428.00 |